Cargando…

No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population

BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) can lead to drastic problems for the patient and its worldwide prevalence is 5%-12%. It also has many comorbidities with other disorders, and the genetic contribution seems the most significant cause. OBJECTIVES: The current study was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eslami Amirabadi, Mohammad Reza, Davari-Ashtiani, Rozita, Khademi, Mojgan, RajeziEsfahani, Sepideh, Emamalizadeh, Babak, Movafagh, Abolfazl, Arabgol, Fariba, Sadr, Said, Darvish, Hossein, Razjouyan, Katayoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584105/
https://www.ncbi.nlm.nih.gov/pubmed/26421175
http://dx.doi.org/10.5812/ircmj.229961v2
_version_ 1782391942150094848
author Eslami Amirabadi, Mohammad Reza
Davari-Ashtiani, Rozita
Khademi, Mojgan
RajeziEsfahani, Sepideh
Emamalizadeh, Babak
Movafagh, Abolfazl
Arabgol, Fariba
Sadr, Said
Darvish, Hossein
Razjouyan, Katayoon
author_facet Eslami Amirabadi, Mohammad Reza
Davari-Ashtiani, Rozita
Khademi, Mojgan
RajeziEsfahani, Sepideh
Emamalizadeh, Babak
Movafagh, Abolfazl
Arabgol, Fariba
Sadr, Said
Darvish, Hossein
Razjouyan, Katayoon
author_sort Eslami Amirabadi, Mohammad Reza
collection PubMed
description BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) can lead to drastic problems for the patient and its worldwide prevalence is 5%-12%. It also has many comorbidities with other disorders, and the genetic contribution seems the most significant cause. OBJECTIVES: The current study was conducted to investigate the association between norepinephrine transporter-3081 (A/T) polymorphisms and ADHD in Iranian population. PATIENTS AND METHODS: Participants were chosen from children and adolescents diagnosed with ADHD referred to Imam Hoseyn Hospital. A child and adolescent psychiatrist confirmed the diagnosis using the Kiddie-Sads-Present and Lifetime Version (K-SADS-PL) semi-structural interview. The control group was from pupils of schools in Tehran (capital city of Iran) who had no history or presence of psychiatric and medical complications. Also, a child and adolescent psychiatrist confirmed their health using the K-SADS-PL semi-structural interview. Genetic examinations were DNA distraction, Polymerase Chain Reaction (PCR), and Restricted Fragment Length Polymorphism (RFLP), which were conducted according to standard protocols. The statistical analysis was performed using chi-square and Fisher's exact test in SPSS version 21. RESULTS: The percentages of ADHD subtypes for combined, inattentive, and hyperactive/impulsive were 72.2%, 17.2%, and 11.9%, respectively. There was no significant association between norepinephrine transporter polymorphism and ADHD (P = 0.81). Moreover, no significant relationship was found between gender [male (P = 0.92) and female (P = 0.63)] and polymorphism. No significant association was found between subtypes of ADHD [combined (P = 0.46), inattentive (P = 0.41), hyperactive/impulsive (P = 0.32)] and polymorphism SCL6A2. This lack of association can also be seen in gender in every subtype. CONCLUSIONS: The results of the study show no significant association between norepinephrine transporter polymorphism SCL6A2 and ADHD.
format Online
Article
Text
id pubmed-4584105
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-45841052015-09-29 No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population Eslami Amirabadi, Mohammad Reza Davari-Ashtiani, Rozita Khademi, Mojgan RajeziEsfahani, Sepideh Emamalizadeh, Babak Movafagh, Abolfazl Arabgol, Fariba Sadr, Said Darvish, Hossein Razjouyan, Katayoon Iran Red Crescent Med J Research Article BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) can lead to drastic problems for the patient and its worldwide prevalence is 5%-12%. It also has many comorbidities with other disorders, and the genetic contribution seems the most significant cause. OBJECTIVES: The current study was conducted to investigate the association between norepinephrine transporter-3081 (A/T) polymorphisms and ADHD in Iranian population. PATIENTS AND METHODS: Participants were chosen from children and adolescents diagnosed with ADHD referred to Imam Hoseyn Hospital. A child and adolescent psychiatrist confirmed the diagnosis using the Kiddie-Sads-Present and Lifetime Version (K-SADS-PL) semi-structural interview. The control group was from pupils of schools in Tehran (capital city of Iran) who had no history or presence of psychiatric and medical complications. Also, a child and adolescent psychiatrist confirmed their health using the K-SADS-PL semi-structural interview. Genetic examinations were DNA distraction, Polymerase Chain Reaction (PCR), and Restricted Fragment Length Polymorphism (RFLP), which were conducted according to standard protocols. The statistical analysis was performed using chi-square and Fisher's exact test in SPSS version 21. RESULTS: The percentages of ADHD subtypes for combined, inattentive, and hyperactive/impulsive were 72.2%, 17.2%, and 11.9%, respectively. There was no significant association between norepinephrine transporter polymorphism and ADHD (P = 0.81). Moreover, no significant relationship was found between gender [male (P = 0.92) and female (P = 0.63)] and polymorphism. No significant association was found between subtypes of ADHD [combined (P = 0.46), inattentive (P = 0.41), hyperactive/impulsive (P = 0.32)] and polymorphism SCL6A2. This lack of association can also be seen in gender in every subtype. CONCLUSIONS: The results of the study show no significant association between norepinephrine transporter polymorphism SCL6A2 and ADHD. Kowsar 2015-07-23 /pmc/articles/PMC4584105/ /pubmed/26421175 http://dx.doi.org/10.5812/ircmj.229961v2 Text en Copyright © 2015, Iranian Red Crescent Medical Journal. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Eslami Amirabadi, Mohammad Reza
Davari-Ashtiani, Rozita
Khademi, Mojgan
RajeziEsfahani, Sepideh
Emamalizadeh, Babak
Movafagh, Abolfazl
Arabgol, Fariba
Sadr, Said
Darvish, Hossein
Razjouyan, Katayoon
No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title_full No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title_fullStr No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title_full_unstemmed No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title_short No Evidence for Association Between Norepinephrine Transporter-3081 (A/T) Polymorphism and Attention Deficit Hyperactivity Disorder in Iranian Population
title_sort no evidence for association between norepinephrine transporter-3081 (a/t) polymorphism and attention deficit hyperactivity disorder in iranian population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584105/
https://www.ncbi.nlm.nih.gov/pubmed/26421175
http://dx.doi.org/10.5812/ircmj.229961v2
work_keys_str_mv AT eslamiamirabadimohammadreza noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT davariashtianirozita noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT khademimojgan noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT rajeziesfahanisepideh noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT emamalizadehbabak noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT movafaghabolfazl noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT arabgolfariba noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT sadrsaid noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT darvishhossein noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation
AT razjouyankatayoon noevidenceforassociationbetweennorepinephrinetransporter3081atpolymorphismandattentiondeficithyperactivitydisorderiniranianpopulation